McKesson Corporation MCK witnessed strong momentum in the year-to-date period. Shares of the company rallied 34.1% compared with 2.9% growth of the industryin the same period. The S&P 500 ...

McKesson (NYSE:MCK) and Oracle (NYSE:ORCL) are among the finalists seeking to acquire electronic medical records company Veradigm (OTC:MDRX), Axios reported Sunday, citing sources. According to ...

I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% ...

Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99 ...